The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

oculis.com

Total Raised

$93.42M

Investors Count

14

Deal Terms

1

Oculis Funding, Oculis Valuation & Oculis Revenue

5 Fundings

Oculis's latest funding round was a Series C for $57M on May 5, 2021.

Oculis's valuation in January 2018 was $94.17M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/5/2021

Series C

$57M

0

FY undefined

12

1/4/2019

Series B - II

$99M

0

FY undefined

10

1/4/2018

Series B

$99M

$94.17M

0

FY undefined

10

12/20/2016

Grant

$99M

0

FY undefined

10

8/12/2016

Series A

0

FY undefined

10

Date

5/5/2021

1/4/2019

1/4/2018

12/20/2016

8/12/2016

Round

Series C

Series B - II

Series B

Grant

Series A

Amount

$57M

$99M

$99M

$99M

Investors

Valuation

$94.17M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

12

10

10

10

10

Oculis Deal Terms

1 Deal Term

Oculis's deal structure is available for 1 funding round, including their Series B from January 04, 2018.

Round

Series B

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Oculis Investors

14 Investors

Oculis has 14 investors. Brunnur Ventures invested in Oculis's Series C funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

8/12/2016

5/5/2021

4
Series A, Series B (2018), Series B - II (2019), Series C (2021)

Venture Capital

Iceland

8/12/2016

5/5/2021

4
Series A, Series B (2018), Series B - II (2019), Series C (2021)

Holding Company

Iceland

1/4/2018

5/5/2021

3
Series B, Series B - II (2019), Series C (2021)

Corporate Venture

Switzerland

00/00/0000

00/00/0000

Pivotal bioVenture Partners

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Bay City Capital

Subscribe to see more

Venture Capital

California

First funding

8/12/2016

8/12/2016

1/4/2018

00/00/0000

00/00/0000

Last Funding

5/5/2021

5/5/2021

5/5/2021

00/00/0000

00/00/0000

Investor

Pivotal bioVenture Partners

Bay City Capital

Rounds

4
Series A, Series B (2018), Series B - II (2019), Series C (2021)
4
Series A, Series B (2018), Series B - II (2019), Series C (2021)
3
Series B, Series B - II (2019), Series C (2021)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Holding Company

Corporate Venture

Venture Capital

Venture Capital

Location

Iceland

Iceland

Switzerland

California

California

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.